Table 3 Antibody-conjugated cytoskeleton-targeting drugs.

From: Roles of cytoskeleton in metastasis: from its mechanism to therapeutic strategies

Drug

Mechanism and features

Clinical progress

Reference

Ado-trastuzumab emtansine

Trastuzumab: antibody targeting HER2 receptor

Emtansine: binds to tubulin and inhibits microtubule assembly

FDA approved

125

Disitamab vedotin

Monomethyl auristatin E: inhibits tubulin polymerization

Hertuzumab: inhibits HER2 receptor dimerization

FDA approved

127

Back to article page